244 related articles for article (PubMed ID: 30034229)
21. Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.
Yoshida H; Kim YH; Iwatsubo S; Sakaguchi C; Sakamori Y; Nagai H; Ozasa H; Mio T; Hirai T
Oncology; 2020; 98(7):460-467. PubMed ID: 32222702
[TBL] [Abstract][Full Text] [Related]
22. Role of emphysema and airway obstruction in prognosis of lung cancer.
Gullón JA; Suárez I; Medina A; Rubinos G; Fernández R; González I
Lung Cancer; 2011 Feb; 71(2):182-5. PubMed ID: 20554345
[TBL] [Abstract][Full Text] [Related]
23. Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer.
Yi YS; Ban WH; Sohng KY
BMC Cancer; 2018 Oct; 18(1):1053. PubMed ID: 30373585
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
[TBL] [Abstract][Full Text] [Related]
26. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
27. Risk of mortality from cardiovascular and respiratory causes in patients with chronic obstructive pulmonary disease submitted to follow-up after lung resection for non-small cell lung cancer.
Volpino P; Cangemi R; Fiori E; Cangemi B; De Cesare A; Corsi N; Di Cello T; Cangemi V
J Cardiovasc Surg (Torino); 2007 Jun; 48(3):375-83. PubMed ID: 17505444
[TBL] [Abstract][Full Text] [Related]
28. Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer.
Li A; Niu FY; Han JF; Lou NN; Yang JJ; Zhang XC; Zhou Q; Xie Z; Su J; Zhao N; Huang Y; Wu YL
Lung Cancer; 2015 Dec; 90(3):375-80. PubMed ID: 26791795
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.
Boros A; Lacroix L; Lacas B; Adam J; Pignon JP; Caramella C; Planchard D; de Montpreville V; Deutsch E; Levy A; Besse B; Le Pechoux C
Oncotarget; 2017 Apr; 8(15):25189-25199. PubMed ID: 28445990
[TBL] [Abstract][Full Text] [Related]
30. Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer.
Ono A; Isaka M; Serizawa M; Omae K; Kojima H; Nakashima K; Omori S; Wakuda K; Kenmotsu H; Naito T; Murakami H; Urakami K; Nagashima T; Sugino T; Kusuhara M; Takahashi T; Yamaguchi K; Ohde Y
Lung Cancer; 2019 Feb; 128():152-157. PubMed ID: 30553548
[TBL] [Abstract][Full Text] [Related]
31. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
32. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data.
Hoang T; Xu R; Schiller JH; Bonomi P; Johnson DH
J Clin Oncol; 2005 Jan; 23(1):175-83. PubMed ID: 15625371
[TBL] [Abstract][Full Text] [Related]
33. Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations.
Lim JU; Yeo CD; Rhee CK; Kim YH; Park CK; Kim JS; Kim JW; Lee SH; Kim SJ; Yoon HK; Kim TJ; Lee KY
PLoS One; 2015; 10(11):e0142306. PubMed ID: 26555338
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
Dingemans AM; Mellema WW; Groen HJ; van Wijk A; Burgers SA; Kunst PW; Thunnissen E; Heideman DA; Smit EF
Clin Cancer Res; 2013 Feb; 19(3):743-51. PubMed ID: 23224737
[TBL] [Abstract][Full Text] [Related]
35. Chronic obstructive pulmonary disease in stage I non-small cell lung cancer that underwent anatomic resection: the role of a recurrence promoter.
Kuo CH; Wu CY; Lee KY; Lin SM; Chung FT; Lo YL; Liu CY; Hsiung TC; Yang CT; Wu YC
COPD; 2014 Aug; 11(4):407-13. PubMed ID: 24475998
[TBL] [Abstract][Full Text] [Related]
36. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Lee SY
Lung Cancer; 2015 Feb; 87(2):155-61. PubMed ID: 25488862
[TBL] [Abstract][Full Text] [Related]
37. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
[TBL] [Abstract][Full Text] [Related]
38. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review.
Palma D; Lagerwaard F; Rodrigues G; Haasbeek C; Senan S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1149-56. PubMed ID: 21640513
[TBL] [Abstract][Full Text] [Related]
39. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
Lee SJ; Lee JI; Nam DH; Ahn YC; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2013 Feb; 8(2):185-91. PubMed ID: 23328548
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Eberhardt WE; de Marinis F; Heeger S; Goddemeier T; O'Byrne KJ; Gatzemeier U
Lung Cancer; 2012 Aug; 77(2):376-82. PubMed ID: 22498112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
